NeuroPace Statistics
Total Valuation
NeuroPace has a market cap or net worth of $437.90 million. The enterprise value is $458.49 million.
Important Dates
The next confirmed earnings date is Tuesday, May 13, 2025, after market close.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NeuroPace has 32.75 million shares outstanding. The number of shares has increased by 12.67% in one year.
| Current Share Class | 32.75M |
| Shares Outstanding | 32.75M |
| Shares Change (YoY) | +12.67% |
| Shares Change (QoQ) | +1.60% |
| Owned by Insiders (%) | 3.63% |
| Owned by Institutions (%) | 41.08% |
| Float | 21.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.87 |
| Forward PS | 4.58 |
| PB Ratio | 50.30 |
| P/TBV Ratio | 54.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.37, with a Debt / Equity ratio of 9.15.
| Current Ratio | 5.37 |
| Quick Ratio | 4.33 |
| Debt / Equity | 9.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.46 |
Financial Efficiency
Return on equity (ROE) is -189.35% and return on invested capital (ROIC) is -15.53%.
| Return on Equity (ROE) | -189.35% |
| Return on Assets (ROA) | -13.39% |
| Return on Invested Capital (ROIC) | -15.53% |
| Return on Capital Employed (ROCE) | -27.26% |
| Revenue Per Employee | $434,272 |
| Profits Per Employee | -$147,505 |
| Employee Count | 184 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 1.69 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +57.29% in the last 52 weeks. The beta is 2.05, so NeuroPace's price volatility has been higher than the market average.
| Beta (5Y) | 2.05 |
| 52-Week Price Change | +57.29% |
| 50-Day Moving Average | 11.60 |
| 200-Day Moving Average | 9.94 |
| Relative Strength Index (RSI) | 66.29 |
| Average Volume (20 Days) | 140,715 |
Short Selling Information
The latest short interest is 393,663, so 1.20% of the outstanding shares have been sold short.
| Short Interest | 393,663 |
| Short Previous Month | 347,479 |
| Short % of Shares Out | 1.20% |
| Short % of Float | 1.85% |
| Short Ratio (days to cover) | 2.38 |
Income Statement
In the last 12 months, NeuroPace had revenue of $79.91 million and -$27.14 million in losses. Loss per share was -$0.93.
| Revenue | 79.91M |
| Gross Profit | 59.09M |
| Operating Income | -21.67M |
| Pretax Income | -31.51M |
| Net Income | -27.14M |
| EBITDA | -21.46M |
| EBIT | -21.67M |
| Loss Per Share | -$0.93 |
Full Income StatementBalance Sheet
The company has $52.76 million in cash and $73.34 million in debt, giving a net cash position of -$20.58 million or -$0.63 per share.
| Cash & Cash Equivalents | 52.76M |
| Total Debt | 73.34M |
| Net Cash | -20.58M |
| Net Cash Per Share | -$0.63 |
| Equity (Book Value) | 8.01M |
| Book Value Per Share | 0.27 |
| Working Capital | 66.18M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.95 million and capital expenditures -$306,000, giving a free cash flow of -$18.26 million.
| Operating Cash Flow | -17.95M |
| Capital Expenditures | -306,000 |
| Free Cash Flow | -18.26M |
| FCF Per Share | -$0.56 |
Full Cash Flow StatementMargins
Gross margin is 73.94%, with operating and profit margins of -27.12% and -33.97%.
| Gross Margin | 73.94% |
| Operating Margin | -27.12% |
| Pretax Margin | -33.97% |
| Profit Margin | -33.97% |
| EBITDA Margin | -26.86% |
| EBIT Margin | -27.12% |
| FCF Margin | n/a |
Dividends & Yields
NeuroPace does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.67% |
| Shareholder Yield | -12.67% |
| Earnings Yield | -6.20% |
| FCF Yield | -4.17% |
Analyst Forecast
The average price target for NeuroPace is $14.83, which is 10.92% higher than the current price. The consensus rating is "Buy".
| Price Target | $14.83 |
| Price Target Difference | 10.92% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 22.40% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NeuroPace has an Altman Z-Score of -4.96 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.96 |
| Piotroski F-Score | 3 |